Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Abstract

The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing—remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modifying therapy. Two hundred and thirty-two patients received at least one GA dose since study initiation in 1991 (mITT cohort), and 100 (43%, Ongoing cohort) continued as of February 2008. Patients were evaluated every 6 months using the Expanded Disability Status Scale (EDSS). Mean GA exposures were 8.6 ± 5.2, 4.81 ± 3.69, and 13.6 ± 1.3 years and mean disease durations were 17, 13, and 22 years for mITT, Withdrawn and Ongoing cohorts, respectively. For Ongoing patients, annual relapse rates (ARRs) maintained a decline from 1.12 ± 0.82 at baseline to 0.25 ± 0.34 per year; 57% had stable/improved EDSS scores (change ≤ 0.5 points); 65% had not transitioned to secondary progressive multiple sclerosis (SPMS); 38%, 18%, and 3% reached EDSS 4, 6, and 8. For all patients on GA therapy (the mITT cohort), ARRs declined from 1.18 ± 0.82 to 0.43 ± 0.58 per year; 54% had stable/improved EDSS scores; 75% had not transitioned to SPMS; 39%, 23%, and 5% reached EDSS 4, 6, and 8. In conclusion, multiple sclerosis patients with mean disease duration of 22 years administering GA for up to 15 years had reduced relapse rates, and decreased disability progression and transition to SPMS. There were no long-term safety issues.

Keywords

disability Expanded Disability Status Scale glatiramer acetate long-term relapsing—remitting multiple sclerosis secondary progressive multiple sclerosis

References

Kremenchutzky M. , Rice GPA , Baskerville J. , Wingerchuk DM , Ebers GC The natural history of multiple sclerosis: a geographically based study. 9: Observations on the progressive phase of the disease. Brain 2006 ; 129: 584-594.

Weinshenker BG , Bass B. , Rice GP , et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-146.

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.

European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.

Panitch H. , Miller A. , Paty D. , Weinshenker B. North American Study Group on interferon beta-1b in secondary progressive MS. Neurology 2004; 63: 1788-1795.

Cohen JA , Cutter GR , Fischer JS , et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.

Bornstein MB , Miller A. , Slagle S. , et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-539.

Wolinsky JS , Narayana PA , O’Connor P. , et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.

Kappos L. , Traboulsee A. , Constantinescu C. , et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006 ; 67: 944-953.

10.

Ebers G. , Traboulsee A. , Langdon D. , Goodin D. , Konieczny A for the Betaseron/Betaferon LTF Study Group. The interferon beta-1b 16-year long-term follow-up study: the results. Presented at the 58th Annual meeting of the American Academy of Neurology , San Diego, CA, 2006: PO1.079.

11.

Kinkel RP , Kollman C. , Glassman A. , et al. Interferon beta-1a (Avonex) delays the onset of clinically definite MS over 5 years of treatment: results from the CHAMPIONS study. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, USA, 2004 : D29.006.

12.

Fisher E. , Rudick RA , Simon JH , et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-1420.

13.

Trojano M. , Pellegrini F. , Fuiani A. , et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306.

14.

Brown MG , Kirby S. , Skedgel C. , et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 2007; 69: 1498-1507.

15.

Johnson KP , Brooks BR , Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.

16.

Johnson KP , Brooks BR , Cohen JA , et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-708.

17.

Johnson KP , Brooks BR , Ford CC , et al. Sustained clinical benefits of glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-266.

18.

Johnson KP , Ford CC , Lisak RP , Wolinsky JS Glatiramer Acetate (Copaxone®): neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005; 111: 42-47.

19.

Ford CC , Johnson KP , Lisak RP , Panitch HS , Shifroni G. , Wolinsky JS A prospective open-label study of glatiramer acetate: Over a decade of continuous use in MS patients. Mult Scler 2006; 12: 309-320.

20.

Vukusic S. , Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206: 135-137.

21.

D’Agostino R. Tutorial in biostatistics propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998; 17: 2265-2281.

22.

Lunceford JK , Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Statist Med 2004; 23: 2937-2960.

23.

Ebers G. , Traboulsee A. , Landon D. , Goodin D. , Reder A. , Konieczny A. , for the Betaseron / Betaferon LTF Study Group. Results from the Interferon Beta-1b 16-year long-term follow-up study. Presented at the 22nd Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Madrid, Spain, September 27-30, 2006: P666.

24.

Ebers G. , Traboulsee A. , Langdon D. , Goodin D. , Konieczny A for the Betaseron / Betaferon LTF Study Group. The interferon beta-1b 16-year long-term follow-up study: the results. Presented at 58th Annual meeting of the American Academy of Neurology, San Diego, CA, 2006: PO1.079.

25.

Goodin DS , Ebers G. , Traboulsee A. , Konieczny A. , for the Betaseron LTF Study Group. The interferon beta-1b 16-year long-term follow-up study: clinical outcomes . Presented at the 131st Annual Meeting of the American Neurological Association, Chicago, IL, October 8-11, 2006: M-3.